Alkermes plc vs Bausch Health Companies Inc.: SG&A Expense Trends

SG&A Expense Trends: Alkermes plc vs. Bausch Health Companies Inc.

In the ever-evolving pharmaceutical industry, understanding the financial health of companies is crucial. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of Alkermes plc and Bausch Health Companies Inc. from 2014 to 2023. Over this period, Alkermes plc has seen a significant increase in SG&A expenses, growing by approximately 245% from 2014 to 2023. In contrast, Bausch Health Companies Inc. has maintained a relatively stable SG&A expense profile, with a modest increase of around 44% over the same period.

The data reveals that while Alkermes plc has been aggressively expanding its operational expenditures, Bausch Health has opted for a more conservative approach. This divergence in financial strategy could reflect differing business models or market strategies. Investors and analysts should consider these trends when evaluating the long-term sustainability and growth potential of these companies.